A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design
Latest Information Update: 23 Jan 2024
At a glance
- Drugs Psilocybin (Primary)
- Indications Abdominal pain
- Focus Adverse reactions
- Sponsors TRYP Therapeutics
Most Recent Events
- 17 Jan 2024 Status changed from planning to recruiting.
- 14 Jul 2023 According to a Tryp Therapeutics media release, company is eager for collaborators at MGH to complete the work necessary to initiate enrolling patients in the study in the coming months.
- 14 Jul 2023 New trial record